Literature DB >> 25332195

Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort.

Pedro Machado, Victoria Navarro-Compán, Robert Landewé, Floris A van Gaalen, Christian Roux, Désirée van der Heijde.   

Abstract

OBJECTIVE: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite measure of disease activity in axial spondyloarthritis. The aims of this study were to determine the most appropriate method for calculating the ASDAS using the C-reactive protein (CRP) level when the conventional CRP level was below the limit of detection, to determine how low CRP values obtained by high-sensitivity CRP (hsCRP) measurement influence ASDAS-CRP results, and to test agreement between different ASDAS formulae.
METHODS: Patients with axial spondyloarthritis who had a conventional CRP level below the limit of detection (5 mg/liter) were selected (n = 257). The ASDAS–conventional CRP with 11 different imputations for the conventional CRP value (range 0–5 mg/liter, at 0.5-mg/liter intervals) was calculated. The ASDAS-hsCRP and ASDAS using the erythrocyte sedimentation rate (ESR) were also calculated. Agreement between the ASDAS formulae was tested.
RESULTS: The ASDAS-hsCRP showed better agreement with the ASDAS-CRP calculated using the conventional CRP imputation values of 1.5 and 2.0 mg/liter and with the ASDAS-ESR than with other imputed formulae. Disagreement occurred mainly in lower disease activity states (inactive/moderate disease activity). When the CRP value was <2 mg/liter, the resulting ASDAS-CRP scores may have been inappropriately low.
CONCLUSION: When the conventional CRP level is below the limit of detection or when the hsCRP level is <2 mg/liter, the constant value of 2 mg/liter should be used to calculate the ASDAS-CRP score. There is good agreement between the ASDAS-hsCRP and ASDAS-ESR; however, formulae are not interchangeable.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25332195     DOI: 10.1002/art.38921

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  17 in total

1.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

2.  Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis.

Authors:  Jean W Liew; Michael M Ward; John D Reveille; Michael Weisman; Matthew A Brown; MinJae Lee; Mohammed Rahbar; Susan R Heckbert; Lianne S Gensler
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

3.  Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort.

Authors:  Roxana Rubio Vargas; Rosaline van den Berg; Miranda van Lunteren; Zineb Ez-Zaitouni; Pauline A C Bakker; Hanne Dagfinrud; Roberta Ramonda; Robert Landewé; Esmeralda Molenaar; Floris A van Gaalen; Désirée van der Heijde
Journal:  RMD Open       Date:  2016-06-16

4.  Relationship of HS CRP and Sacroiliac Joint Inflammation in Undifferentiated Spondyloarthritis.

Authors:  Te-Jung Liu; Cheng-Chiang Chang; Liang-Cheng Chen; Heng-Yi Chu; Chun-Sheng Hsu; Shin-Tsu Chang
Journal:  Open Med (Wars)       Date:  2018-05-19

5.  Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study.

Authors:  Xiaojian Ji; Yiwen Wang; Yingpei Ma; Zhengyuan Hu; Siliang Man; Ying Zhang; Kunpeng Li; Jinshui Yang; Jian Zhu; Jianglin Zhang; Feng Huang
Journal:  Biomed Res Int       Date:  2019-02-25       Impact factor: 3.411

6.  A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Authors:  Atul Deodhar; Lianne S Gensler; Jonathan Kay; Walter P Maksymowych; Nigil Haroon; Robert Landewé; Martin Rudwaleit; Stephen Hall; Lars Bauer; Bengt Hoepken; Natasha de Peyrecave; Brian Kilgallen; Désirée van der Heijde
Journal:  Arthritis Rheumatol       Date:  2019-05-28       Impact factor: 10.995

7.  Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China.

Authors:  Xiaojian Ji; Yiwen Wang; Zhengyuan Hu; Yingpei Ma; Siliang Man; Kunpeng Li; Yanyan Wang; Jian Zhu; Jianglin Zhang; Feng Huang
Journal:  Front Pharmacol       Date:  2019-12-17       Impact factor: 5.810

8.  Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.

Authors:  Atul Deodhar; Désirée van der Heijde; Joachim Sieper; Filip Van den Bosch; Walter P Maksymowych; Tae-Hwan Kim; Mitsumasa Kishimoto; Andrew Ostor; Bernard Combe; Yunxia Sui; Alvina D Chu; In-Ho Song
Journal:  Arthritis Rheumatol       Date:  2021-11-12       Impact factor: 15.483

9.  Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.

Authors:  Adrian Ciurea; Pascale Exer; Ulrich Weber; Giorgio Tamborrini; Beate Steininger; Rudolf O Kissling; Jürg Bernhard; Almut Scherer
Journal:  Arthritis Res Ther       Date:  2016-03-22       Impact factor: 5.156

10.  Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy.

Authors:  Agata Sebastian; Patryk Wojtala; Łukasz Lubiński; Małgorzata Mimier; Arkadiusz Chlebicki; Piotr Wiland
Journal:  Reumatologia       Date:  2017-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.